RBC Capital analyst Lisa Walter initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating and $478 price target The firm says the company is pioneering the rare genetic obesity market with MC4R agonists which target the root cause of disease. RBC thinks Rhythm’s Imcivree business can reach over $2B in revenue by 2030 with the hypothalamic obesity launch and expansion into the larger Prader-Willi syndrome indication. The company is well positioned for future growth, contends RBC.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity
- Rhythm Pharmaceuticals price target raised to $145 from $129 at Wells Fargo
- Rhythm Pharmaceuticals price target raised to $125 from $123 at H.C. Wainwright
- Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA
- Rhythm Pharmaceuticals: Raising Revenue Forecasts and Price Target on Strengthening BBS Growth and Clear aHO Catalyst Path